Nycomed and Forest Laboratories have entered into a collaboration and distribution agreement for Daxas in the U.S. Daxas is a proprietary selective phosphodiesterase 4 (PDE4) enzyme inhibitor that has been developed by Nycomed for the treatment of COPD (chronic obstructive pulmonary disease) and for which Nycomed submitted an NDA with the FDA in July. Forest will make an upfront payment to Nycomed of $100 million and will pay undisclosed milestone payments. In addition, Nycomed will receive r...